This paper gives an important warning about drug repurposing: a drug that looks anti-inflammatory in one setting may behave differently inside a complex disease environment.
Epalrestat is an aldose reductase inhibitor used for diabetic neuropathy. Because aldose reductase is linked with inflammation, the researchers explored whether epalrestat could help rheumatoid arthritis. In cell experiments, epalrestat reduced inflammatory signals. But in arthritis animal models, epalrestat alone unexpectedly worsened disease. It increased toxic lipid peroxidation products such as 4-HNE and MDA, raised inflammatory markers, and increased Th17-related immune activity.
The breakthrough came when epalrestat was combined with N-acetylcysteine, an antioxidant. This combination reduced toxic aldehydes, lowered inflammatory cytokines, improved joint condition, decreased Th17 cells, and increased regulatory T-cell signals. In other words, the antioxidant helped turn a risky treatment effect into a more useful anti-arthritic strategy.
The novelty of this paper is its balanced view of inflammation. It shows that immune tolerance is not controlled by immune pathways alone. Oxidative stress and toxic metabolic by-products can push the immune system toward inflammation and disturb T-cell balance.
For the cluster topic of immune tolerance, the study shows that restoring immune balance may require cleaning up harmful chemical stress signals, not only blocking immune cells. It also suggests that future RA treatment, especially in patients with diabetic complications, may need carefully designed combinations that consider both inflammation and metabolic safety.
References
X. Chen et al., “IFN-γ-primed MSC extracellular vesicles attenuate rheumatoid arthritis via PD-L1-driven T-cell suppression and bone preservation,” Journal of Controlled Release, vol. 395, article 114985, 2026. Doi: 10.1016/j.jconrel.2026.114985
